Early Antibody–Drug Conjugates (ADCs) exhibited side-effect profiles similar to those of ‘classical’ chemotherapeutic agents and their results in clinical trials in cancer patients were generally poor. However, recent clinical development of ADCs that have highly potent tubulin-acting agents as their payloads have greatly changed the outlook for ADC technology. Enhancing the cancer cell-killing activity of antibodies through conjugation to highly potent cytotoxic ‘payloads’ to create ADCs offers a strategy for developing anti-cancer drugs of great promise.
(Source: John M Lambert, Drug-conjugated antibodies for the treatment of cancer (http://onlinelibrary.wiley.com/doi/10.1111/bcp.12044/abstract), 2013)
SMi's masterclass hosted by PAREXEL International will discuss ADCs which are being clinically tested in a range of oncology indications. In the absence of specific guidance on the development of ADCs, this workshop aims to help participants understand the CMC issues during the development, with a particular focus on the assessment and control of the quality of such products.
Benefits of Attending
• Identify key parameters for non-clinical studies to support a Phase 1 clinical trial
• Consider the factors that influence the choice of conjugate and linker types
• Learn how to create an early phase product development plan that meets regulatory expectations
• Network with and learn from senior industry representatives
To view the full conference programme, visit www.smi-online.co.uk/2013adc-development12.asp
Contact
Daniel Lee
